BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05983770 (Tegoprubart in Prevention of rejection in kidney transplantation): BVCT ex-ante prediction vs. reported outcome

On 26 Jan 2025, BioinvestGPT's BVCT predicted technical partial success and commercial partial success for this trial. The 6 Nov 2025 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially probably insufficient.

Clinical Trial

NCTID
NCT05983770
Acronym
BESTOW
Drug Name
Tegoprubart
Drug MoA
anti-CD40L inhibitor
Drug Modality
monoclonal antibody (mAb)
Drug Class
First-In-Class
Therapeutic Area
Immune System Diseases
Indication
Prevention of rejection in kidney transplantation
Human Patients
127
Sponsor
Eledon Pharmaceuticals
Phase
Phase 2

Prediction of , index 1887

Prospective Prediction
Prediction Index
1887
Prediction Date
Commercial Prediction
partial SUCCESS (commercially maybe sufficient yet weak additive clinical benefit in eGFR/graft survival/BPAR at most numerically superior to tacrolimus)
Technical Prediction
partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in eGFR at most numerically superior to tacrolimus featuring negative dose-response relationship)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
284 days in advance
Readout Data Interpretation
tegoprubart + SoC failed to achieve superiority in eGFR compared with tacrolimus + SoC
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially probably insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
AT-1501-K207: BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
Phase
Phase 2
Status
Completed
Enrollment
127
Lead sponsor
Eledon Pharmaceuticals
Conditions
Kidney Transplant Rejection
Interventions
DRUG: AT-1501; DRUG: Tacrolimus
Design
Randomized · Parallel · None
Primary purpose
Treatment
Start
2023-08-30
Primary completion
2025-09-11
Completion
2025-09-25
Primary outcomes
  • eGFR at 12 months (Assessed from date of transplant through Day 364 (Month 12))

NCT05983770 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials